{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:26:10Z","timestamp":1715387170358},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"DOI":"10.7759\/cureus.60027","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:37:58Z","timestamp":1715337478000},"source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic Strategy for Functional Metastatic Malignant Paraganglioma: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Yousra","family":"Bennouna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadin","family":"Shawar Al Tamimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganiou","family":"Adjade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El Fadli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Essadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","author":"Lenders JW","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, et al.. Phaeochromocytoma. Lancet. 2005,","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1862","article-title":"Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes","volume":"91","author":"Benn DE","year":"2006","unstructured":"Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al.. Clinical presentation and penetrance of pheochromocytoma\/paraganglioma syndromes. J Clin Endocrinol Metab. 2006, 91:827-36. 10.1210\/jc.2005-1862","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970410","article-title":"Diagnostic management of benign and malignant pheochromocytoma","volume":"115","author":"Scholz T","year":"2007","unstructured":"Scholz T, Schulz C, Klose S, Lehnert H. Diagnostic management of benign and malignant pheochromocytoma. Exp Clin Endocrinol Diabetes. 2007, 115:155-9. 10.1055\/s-2007-970410","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00831","article-title":"Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management-an updated review","volume":"10","author":"Bocchini M","year":"2020","unstructured":"Bocchini M, Nicolini F, Severi S, et al.. Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management-an updated review. Front Oncol. 2020, 10:831. 10.3389\/fonc.2020.00831","journal-title":"Front Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)48792-1","article-title":"A case of nonfunctioning paraganglioma arising from the retroperitoneum: angiographic and scintigraphic features","volume":"133","author":"Oguma S","year":"1985","unstructured":"Oguma S, Okazaki H, Nakamichi G, Endo Y. A case of nonfunctioning paraganglioma arising from the retroperitoneum: angiographic and scintigraphic features. J Urol. 1985, 133:73-6. 10.1016\/s0022-5347(17)48792-1","journal-title":"J Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar L","year":"2007","unstructured":"Amar L, Baudin E, Burnichon N, et al.. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab. 2007, 92:3822-8. 10.1210\/jc.2007-0709","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0396","article-title":"Clinical management of paragangliomas","volume":"171","author":"Corssmit EP","year":"2014","unstructured":"Corssmit EP, Romijn JA. Clinical management of paragangliomas. Eur J Endocrinol. 2014, 171:R231-43. 10.1530\/EJE-14-0396","journal-title":"Eur J Endocrinol"},{"key":"ref8","article-title":"Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas","volume":"63","author":"Gimenez-Roqueplo AP","year":"2003","unstructured":"Gimenez-Roqueplo AP, Favier J, Rustin P, et al.. Mutations in the SDHB gene are associated with extra-adrenal and\/or malignant phaeochromocytomas. Cancer Res. 2003, 63:5615-21.","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven AK","year":"2019","unstructured":"Stueven AK, Kayser A, Wetz C, et al.. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. Int J Mol Sci. 2019, 20:10.3390\/ijms20123049","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00787-z","article-title":"Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Ilanchezhian M","year":"2020","unstructured":"Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol. 2020, 21:85. 10.1007\/s11864-020-00787-z","journal-title":"Curr Treat Options Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch SD","year":"1988","unstructured":"Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988, 109:267-73. 10.7326\/0003-4819-109-4-267","journal-title":"Ann Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12542","article-title":"Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis","volume":"81","author":"Niemeijer ND","year":"2014","unstructured":"Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP. Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf). 2014, 81:642-51. 10.1111\/cen.12542","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux J","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY, et al.. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014, 135:2711-20. 10.1002\/ijc.28913","journal-title":"Int J Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-011-9189-0","article-title":"Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma","volume":"23","author":"Favier J","year":"2012","unstructured":"Favier J, Igaz P, Burnichon N, et al.. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol. 2012, 23:34-42. 10.1007\/s12022-011-9189-0","journal-title":"Endocr Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040436","article-title":"Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies","volume":"11","author":"Pang Y","year":"2019","unstructured":"Pang Y, Liu Y, Pacak K, Yang C. Pheochromocytomas and paragangliomas: from genetic diversity to targeted therapies. Cancers (Basel). 2019, 11:10.3390\/cancers11040436","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane GM","year":"2019","unstructured":"O'Kane GM, Ezzat S, Joshua AM, et al.. A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer. 2019, 120:1113-9. 10.1038\/s41416-019-0474-x","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000347","article-title":"Phase 2 study of pembrolizumab in patients with advanced rare cancers","volume":"8","author":"Naing A","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, et al.. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020, 8:10.1136\/jitc-2019-000347","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1220687","article-title":"Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001)","volume":"41","author":"Druce MR","year":"2009","unstructured":"Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res. 2009, 41:697-702. 10.1055\/s-0029-1220687","journal-title":"Horm Metab Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh DY","year":"2012","unstructured":"Oh DY, Kim TW, Park YS, et al.. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas. Cancer. 2012, 118:6162-70. 10.1002\/cncr.27675","journal-title":"Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/247503-therapeutic-strategy-for-functional-metastatic-malignant-paraganglioma-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T10:38:01Z","timestamp":1715337481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/247503-therapeutic-strategy-for-functional-metastatic-malignant-paraganglioma-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.60027","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}